After the government secured 300 million doses of Biological E’s coronavirus vaccine candidate, Cobrevax, which is still in late stage trials, all eyes are on the made-in-India vaccine maker. To add to the anticipation, it has now been reported that the vaccine could be 90 per cent effective against coronavirus.
Dr N K Arora, Chairman of India’s COVID-19 Working Group of the National Technical Advisory Group on Immunisation, told NDTV that “according to the company, Biological E’s vaccine, which will be dubbed Corbevax, is identical to the Novavax vaccination, which is more than 90% effective against Covid variations.”
“A very similar Indian vaccine is also under phase 3 trial, which is the Bio E vaccine. These vaccines are exciting because we have previous experience on a similar platform. They are safe across the age groups and have very high effectiveness,” he said.
The vaccine will be available for Rs 250 for two doses.
Dr Arora also expressed confidence that soon India will be world supplier of covid vaccines as he said, “This may sound presumptuous. Ultimately the world will be dependent on us for vaccines. It is very premature, very presumptuous.”
“I’m aware that everybody is looking forward to India. Because most of the poor countries and low-income countries have no source. Today it is easier to buy weapons than to buy vaccines,” he said.
